Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina M Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Naomi Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with CLL. Initial results showed that ibrutinib-containing regimens had superior PFS and rituximab did not add additional benefit. Here we present an updated analysis. With median follow-up of 55 months, median PFS was 44 months (95% CI 38-54) for BR and not yet reached in either ibrutinib-containing arm. 48-month PFS estimates were 47%, 76% and 76% for BR, ibrutinib, and IR respectively...
January 12, 2024: Blood